Treatment of deep venous thrombosis in pregnant women.

Abstract

The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour post-dose measurements of anti-Xa activity. Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. Four-hour post-dosage plasma anti-Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti-Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice-daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti-Xa.

• Authors: Jacob A Lykke, Thor Grønlykke, Jens Langhoff-Roos
• Journal: Acta obstetricia et gynecologica Scandinavica (Acta Obstet Gynecol Scand) Vol. 87 Issue 11 Pg. 1248-51 ( 2008) ISSN: 1600-0412 [Electronic] United States
• PMID: 18850332 (Publication Type: Journal Article)

Chemical References

• Factor Xa Inhibitors
• Fibrinolytic Agents
• Heparin, Low-Molecular-Weight
• Tinzaparin

Topics

• Adult
• Dose-Response Relationship, Drug
• Factor Xa Inhibitors
• Female
• Fibrinolytic Agents (therapeutic use)
• Gestational Age
• Heparin, Low-Molecular-Weight (therapeutic use)
• Humans
• Parity
• Pregnancy
• Pregnancy Complications, Cardiovascular (drug therapy)
• Pregnancy Outcome
• Retrospective Studies
• Risk Assessment
• Tinzaparin
• Treatment Outcome
• Venous Thrombosis (drug therapy)